Provided by Tiger Trade Technology Pte. Ltd.

ADMA Biologics

16.43
+0.49003.07%
Post-market: 16.450.0200+0.12%19:16 EST
Volume:1.59M
Turnover:26.08M
Market Cap:3.91B
PE:19.19
High:16.60
Open:16.31
Low:16.09
Close:15.94
52wk High:25.67
52wk Low:13.50
Shares:238.00M
Float Shares:233.86M
Volume Ratio:0.74
T/O Rate:0.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8560
EPS(LYR):0.8100
ROE:63.17%
ROA:21.76%
PB:9.07
PE(LYR):20.28

Loading ...

GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Total Revenue About $635M, vs. FactSet Est of $631.9M

MT Newswires Live
·
Jan 12

ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million

Reuters
·
Jan 12

ADMA Biologics Inc - FY 2025 Preliminary Unaudited Total Revenue About $510-$511 Mln

THOMSON REUTERS
·
Jan 12

ADMA Biologics Inc - Expects FY 2026 Revenue $635 Mln, FY 2027 $775 Mln

THOMSON REUTERS
·
Jan 12

ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

THOMSON REUTERS
·
Jan 12

ADMA Biologics Outlook FY Revenue USD 635 Million

THOMSON REUTERS
·
Jan 12

ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

GlobeNewswire
·
Jan 05

The Bull Case For ADMA Biologics (ADMA) Could Change Following Its Higher 2025 Revenue Outlook Revision

Simply Wall St.
·
Dec 23, 2025

ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares

Reuters
·
Dec 17, 2025

ADMA Biologics (ADMA): Assessing Valuation as Short Interest Declines and Market Sentiment Improves

Simply Wall St.
·
Nov 27, 2025

High Growth Tech Stocks In The US For November 2025

Simply Wall St.
·
Nov 24, 2025

ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares

Reuters
·
Nov 22, 2025

ADMA Biologics (ADMA) Receives a New Rating from Cantor Fitzgerald

TIPRANKS
·
Nov 06, 2025

ADMA Biologics Reports Strong Q3 2025 Financial Results

TIPRANKS
·
Nov 06, 2025

Stock Track | ADMA Biologics Plunges 5.72% After-Hours Despite Strong Q3 Results and Raised Guidance

Stock Track
·
Nov 06, 2025

BRIEF-ADMA Biologics Q3 Revenue USD 134.2 Million

Reuters
·
Nov 06, 2025

ADMA Biologics Inc Outlook 2026 Total Revenue: Raised to at Least $630 Million

THOMSON REUTERS
·
Nov 06, 2025

ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 06, 2025

Adma Biologics options imply 14.3% move in share price post-earnings

TIPRANKS
·
Nov 06, 2025

Stock Track | ADMA Biologics Soars 5% Ahead of Expected Strong Q3 Earnings Report

Stock Track
·
Nov 06, 2025